-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The annual American Society of Hematology (ASH) annual meeting is one of the largest and most comprehensive international academic conferences in the field of hematology in the world
.
This year, the 63rd ASH Annual Conference will be held offline and online from December 11th to 14th.
At present, the much-anticipated blockbuster study Late-Breaking Abstracts (LBA) has been announced.
Let's take a look together
.
01 Abstract Number: LBA-1 Topic: The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.
Speaker: Hervé Tilly Unit: Department of Hematology and U1245, Centre Henri Becquerel and University of Rouen, Rouen, France Report time: Tuesday, December 14, 2021, 9:00 AM-10 :30 AM02 Abstract Number: LBA-2 Topic: The Longitudinal Dynamics and Natural History of Clonal Hematopoiesis.
Speaker: Margarete A Fabre Unit: University of Cambridge, Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom Reporting time: Tuesday , December 14, 2021, 9:00 AM-10:30 AM03 Abstract Number: LBA-3 Topic: Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia:First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B).
Speaker: Alok Srivastava Unit: Department of Hematology, Christian Medical College, Vellore, India Time of report: Tuesday, December 14, 2021, 9:00 AM-10:30 AM04 Abstract Number: LBA-4 Topic: Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia.
Speaker: Masayuki Umeda Unit ：Department of Pathology, St.
Jude Children’s Research Hospital, Memphis, TN Report Time: Tuesday, December 14, 2021, 9:00 AM-10:30 AM05 Abstract Number: LBA-5 Topic: Effectiveness of rFVIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study.
Speaker: Lynn Malec Unit: Versiti Blood Research Institute, Milwaukee, WI Reporting time: Tuesday, December 14, 2021, 9:00 AM- 10:30 AM06 Abstract Number: LBA-6 Topic: Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study.
Speaker: Michael R.
Bishop Unit: The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL Report time: Tuesday, December 14, 2021, 9:00 AM-10:30 AM for more exciting follow-up reports, please read the original text "We make progress together
.
This year, the 63rd ASH Annual Conference will be held offline and online from December 11th to 14th.
At present, the much-anticipated blockbuster study Late-Breaking Abstracts (LBA) has been announced.
Let's take a look together
.
01 Abstract Number: LBA-1 Topic: The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.
Speaker: Hervé Tilly Unit: Department of Hematology and U1245, Centre Henri Becquerel and University of Rouen, Rouen, France Report time: Tuesday, December 14, 2021, 9:00 AM-10 :30 AM02 Abstract Number: LBA-2 Topic: The Longitudinal Dynamics and Natural History of Clonal Hematopoiesis.
Speaker: Margarete A Fabre Unit: University of Cambridge, Wellcome-MRC Cambridge Stem Cell Institute, Cambridge, United Kingdom Reporting time: Tuesday , December 14, 2021, 9:00 AM-10:30 AM03 Abstract Number: LBA-3 Topic: Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia:First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B).
Speaker: Alok Srivastava Unit: Department of Hematology, Christian Medical College, Vellore, India Time of report: Tuesday, December 14, 2021, 9:00 AM-10:30 AM04 Abstract Number: LBA-4 Topic: Integrated Genomic Analysis Identifies UBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia.
Speaker: Masayuki Umeda Unit ：Department of Pathology, St.
Jude Children’s Research Hospital, Memphis, TN Report Time: Tuesday, December 14, 2021, 9:00 AM-10:30 AM05 Abstract Number: LBA-5 Topic: Effectiveness of rFVIIFc for First-Time Immune Tolerance Induction (ITI) Therapy: Final Results from the Global, Prospective VerITI-8 Study.
Speaker: Lynn Malec Unit: Versiti Blood Research Institute, Milwaukee, WI Reporting time: Tuesday, December 14, 2021, 9:00 AM- 10:30 AM06 Abstract Number: LBA-6 Topic: Tisagenlecleucel Vs Standard of Care As Second-Line Therapy of Primary Refractory or Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma: Analysis of the Phase III Belinda Study.
Speaker: Michael R.
Bishop Unit: The David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL Report time: Tuesday, December 14, 2021, 9:00 AM-10:30 AM for more exciting follow-up reports, please read the original text "We make progress together
